If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent ...

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the release of five-year follow-up results for the Intismeran vaccine used ...

In the latest close session, Moderna (MRNA) was down 3.45% at $42.55. The stock's change was less than the S&P 500's daily gain of 0.54%. At the same time, the Dow added 1.05%, and the tech-heavy ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. MRNY, the YieldMax MRNA Option Income Strategy ETF, ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Moderna and Merck previously reported five-year follow-up data from their Phase 2b KEYNOTE-942 trial, showing that the personalized mRNA cancer therapy intismeran autogene combined with Keytruda cut ...